Clin2
NCT07593209Possibly a fitRecruiting

New PET scan tracer for detecting cancer using EphA2

Malignant Tumor

Part of Cancer clinical trials.

This study tests a new radioactive tracer (a type of dye) called 68Ga-DOTA-EphA2 that helps PET scanners find cancer cells. Researchers want to see if this tracer can better identify tumors in patients who may have cancer.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
30 people
Ages
18 years to 80 years
Study type
Observational

Who can take part

  • You are 18–80 years old
  • You have suspected or confirmed cancer with at least one tumor large enough to be seen on imaging (CT, MRI, or ultrasound)
  • You are in good enough overall health to have a PET/CT scan (ECOG score of 0–2, meaning you can do most daily activities)
  • Your liver, kidneys, heart, and lungs work well enough for safe PET/CT imaging
  • You have not been in another drug or radioactive imaging study in the past 4 weeks
  • You can hold still during a PET/CT scan and understand the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07144085Recruiting· Phase 1
Testing a new PET scan tracer for cancer diagnosis

This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.

Shenyang, Liaoning
NCT07459192Not yet recruiting
New PET scan to find cancer spread

This trial uses a special PET scan with a new tracer called 68Ga-DOTA-BLP to spot cancer and its spread in the body. It aims to see if this scan can find tumors in lymph nodes or other areas without needing more painful biopsies.

Chongqing, Chognqing
NCT06844110Recruiting
New PET scan for cancer using CD73 probe

This trial tests a new PET imaging agent that targets CD73, a protein found on many cancer cells. It may help doctors see tumors more clearly without chemotherapy or radiation before the scan.

Dongcheng, Beijing Municipality
NCT07400263Recruiting
Testing a new imaging agent for epithelial tumors

This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.

Beijing, Beijing Municipality
NCT06696326Recruiting
New PET scan for prostate cancer detection

This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.

Xiamen, Fujian
NCT07023640Recruiting
Imaging test for tumors using a new tracer agent

This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.

Beijing, Beijing Municipality

Hear when a new Malignant Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.